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Preface 
This dissertation is submitted for the degree of Master of Science in Medicine (MSc Med) in 
Bioinformatics at the Division of Computational Biology in the Department of Integrative 
Biomedical Sciences (IBMS), The Faculty of Health Sciences, University of Cape Town, South 
Africa. The study was approved by the Human Research Ethics Committee (HREC) of the 
University of Cape Town, South Africa (604/2015) and supported by the National Research 
Fund (Bioinformatics and Functional Genomics Grant). The work reported in this dissertation 
resulted from data collected and owned by Dr. Heather Jaspan for the Project titled: Early 
Introduction of Non-Breast milk Foods Activates HIV Target Cells in South African Infants. The 
data was generated from; collected baby stool samples (microbial compositions) and collected 
blood samples (gene expression levels). 
The work is split into 4 chapters were the first looks to show and discuss literature based on 
the influence of gut microbiota on the immune system in infants. The second chapter looks at 
the methods that went into the research and computation that went into looking at the influence 
of gut microbiota on the immune system in infants. The third chapter is data analysis and 
results. The last chapter focuses on the conclusion and future work. The study looks at the 
correlation of microbial profiles and gene expression data for infants in their first 14 weeks. 
The data collected 0, 6 and 14 weeks was; microbial compositions, gene expression levels 
and feeding modality. The submitted material is the work of the MSc candidate, unless stated 
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With respect to the gut, these are microbiota that live in the gut but do not harm the host. 
These organisms benefit from inhabiting the host and in some instances may provide 
beneficial functions or beneficial bi-products that come from the organism’s functions. This is 
known as mutualistic behaviour with the human host [1]. 
 
Cytokines: 
 These are small proteins that are secreted and released by the host’s immune cells and are 
involved in cell signalling. They have a specific effect (in order to illicit an immune response) 
on communications, exchanges and interactions that can occur between cells [2] and can be 
pro or anti-inflammatory. “Cytokine is a general name; other names include: lymphokine 
(produced by lymphocytes), monokine (produced by monocytes), chemokine (have 
chemotactic activities) and interleukin (produced by but act on other leukocytes). They can act 
on the cells that secrete them (autocrine action), on nearby cells (paracrine action) or on 
distant cells (endocrine action)” [2]. 
 
Gut microbiota homeostasis: 
This is where a system (microbiota) maintains a relatively stable state of equilibrium which is 
balance of its internal intertwined and interdependent factors through constant regulatory 
mechanisms. With respect to the gut, this is constantly maintaining a balanced environment 
between the microbes present, products from their various processes, the host’s immune 
system and the epithelial tissue that lines the intestine. The control factors to take into account 
are the uptake of nutrients by the host and microbes, host’s immune responses, cell growth of 
the different microbial communities, quorum sensing of the microbial communities present and 
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the regeneration of the epithelial tissue. This homeostatic state is important to maintain as 
some essential processes such as some metabolic and immune processes can only take 
place in a homeostatic environment. Dysbiosis is the opposite of homeostasis and is the state 
when one or more of the control factors are disrupted which can result in a change in the 
composition microbial groups [3] . 
Microbiome: 
This is a compilation of different microbial groups, their genomes and functions. This 
population is present in a particular environmental habitat or area. For example, the various 
human body parts have their own microbiomes, such as, the mouth cavity microbiome is 
different to the skin or gut one, but they all make up one microbiome, the human one [4], [5]. 
Microbiota: 
This is a compilation of various organisms which form a population and are living in an 
environment, in our case, the gut. These organisms range from bacteria to eukaryotes [5]. 
Operational taxonomic unit (OTU): 
In biological classification, these are a group of organisms that have their  16S rRNA gene 
sequences clustered together as they have closely related sequences [1]. These clusters 
roughly represent the grouping of taxa at phylogenetic levels. A user can define sequence 
similarity cut-off to a preferred percentage depending on the quality of their dataset [6]. The 
general cut-off is 95 % similarity and the sequences are assigned to the same genus and 
those with 97% similarity to the assigned to the same species [6], [7]. 
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Pathogen: 
This is any agent that can cause disease. In the gut, microbes are usually chief culprits and 
achieve disease state by evading the host’s immune system via interactions such as the host-
pathogen interactome [8].  
Relative abundance: 
This is a component of biodiversity and measures of the total number of organisms, sequences 
or OTUs present in a community or a sample, in relation to all the others that are present in 
the same community or sample [9]. 
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Abstract 
Background and Methods: Microbiota play many significant, direct or indirect, beneficial and 
detrimental roles in humans. Microbiome development is established at infancy where diet 
plays a directive role in the proliferation of gut microbes. It has been shown that the presence 
of a defined set of microbes has been known to increase the overall immunological capacity, 
which vaccines depend on to be effective. To date, little work has been done on the effect of 
the microbiota on immune system at infancy, thus an analysis of the microbial ecology present 
in the infant’s gut and its correlation with immune activation is needed. Expression of genes 
involved in mediating and regulating immunity can be measured as an indicator of immune 
activity. Vaccines work by stimulating an immune response which can be measured by gene 
expression levels. This affects the infant’s ability to establish a strong immune system, which 
is also dictated at infancy. 16s rRNA sequence data generated from 134 infant stool samples, 
at vaccination points 0, 6 and 14 weeks from infants that were either breast or formula fed, 
was analysed using the Quantitative Insights Into Microbial Ecology (QIIME) pipeline to detect 
different taxonomic groups that make up a particular microbiome. Statistical analysis in R was 
used to quantify the diversity of the different microbial groups in the gut. Expression levels of 
immune-related genes were measured from blood samples that were stimulated by a Bacillus 
Calmette–Guérin (BCG) antigen and correlated with microbiota compositions. 
Results and Conclusion: Microbiome data showed initial differentiation between breast and 
mixed fed infants.15% of 5 of the most abundant bacteria for breast fed infants were 
Bifidobacteriales, which are known for their probiotic properties. The data did not fully cluster 
as the oldest samples were taken quite early at 14 weeks. Individual bacteria were correlated 
with individual gene expression level data. The study shows the relative abundance of 
particular bacteria, comparing against feeding modality and demonstrated how the microbiota 
correlates with gene expression levels. At week 14, Bifidobacterium of abundance below 0 
(heatmap log₁₀ scale) generally correlated with high CASP3 gene expression levels in breast 
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fed babies while abundances above 1 correlated with low gene expression levels. Gene 
expression at abnormal levels usually has undesirable effects which result in dysfunctional 




















Chapter 1: Literature Review - Influence of Gut Microbiota 
on the Immune System in Infants 
 
1.1 Infant Microbiome 
	
The advancements in ease, accuracy and speed of DNA Sequencing has unlocked a wealth 
of opportunities. In particular, the ability to identify different species present in samples. These 
species can not only be identified but quantified. Downstream, we have the ability to note the 
functional properties of the different species present and compute statistical analysis based 
on the quantities present. Here we take a closer look at microbial communities in the human 
host’s gut. The gut microbiota [10] is host to the largest number and most diverse community 
of organisms [11]. The gut microbiota is also quite interesting, with respect to diversity, as 
compositions differ from host to host regardless of their health status. Much research has gone 
into looking at possible commonalities, for example, of a healthy gut. 
 
The microbiota is known to have beneficial and detrimental effects [12] on humans where 
these effects may be directly or indirectly linked to a group or groups of bacterial species. An 
appreciation of this will afford us great insights into health solutions [13] especially when 
looking at personalised health solutions (drug wise and nutritional) [12]. Development of the 
microbiome is dictated at infancy [14] and is important to establish healthy growth moving 
forward. Various studies have looked to understanding the change in diversity and 
composition over time in an effort to gain insight on when and how a particular host’s microbial 
profile is set. The microbiome at infancy influences healthy growth, metabolic functionality [14], 
maturation of the gut, brain and immune development [15]. Recent studies have shed a lot of 
light on understanding the changes in the microbiome, in particular, when looking at the first 
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year of life [16], [17].  The microbial composition varies between individuals and the 
environment that the microbiome interacts with is quite dynamic [18]. 
 
There are long term effects associated with the initial colonization of the gut. The gut 
microbiome is developed via colonisation of the gut by bacteria and this is influenced by a 
number of factors which include  the type of diet (breast fed or mixed fed is breast milk and/or 
other foods) and the environment (e.g. urban vs. rural settings) the infant is exposed to [19]–
[21]. With respect to ‘other foods’ in mixed fed, at infancy the alternative to breast is formula 
milk. There are other factors that are suggested to be at play in the development of the 
microbiome that occurs before, during or just after birth [22]–[25]. It was noted that their roles 
are probably as significant as those played by factors after birth such as diet. The suggested 
factors include maternal factors such as the type of diet the mother is on and the different 
antibiotics in use [26], [27], fetus related factors such as gestational age, and lastly, birth 
related factors like mode of delivery (vaginal vs. caesarean birth) [21], [28]–[30].  
 
An interesting factor mentioned above is gestational age, which has a strong influence on the 
maturity of the infant gut microbiome. When comparing the fecal microbiota of a preterm infant 
vs. a full term one, there is a difference in pathogenic bacteria, which are more abundant in 
the preterm infants [31]. A suggested explanation may be that, the mother’s own microbiome 
changes in diversity and composition over time. This may be to prepare an appropriate 
microbiome composition that is fit to be transferred and colonize the infant. Preterm infants, 
may be born before the maternal microbiome has reached this stage. A limited number of 
studies have looked at fecal samples as a true representation of the true diversity and 
composition in the gut microbiome. It has been seen that there is variability in terms of 
abundance and composition when comparing the small intestine and the colon but fecal 




Another interesting factor that has also been found to have a strong influence is the 
environment [33]. In particular, when looking at the familial environment; the presence of 
siblings is a huge contributing factor to the development of the microbiota. The familial 
environment has attributes such as their geographical location and/or their culture. A rural 
location and culture will vary to a crowded unsanitary setting; it will also differ with a more 
affluent urban setting. It is also important to note that cleaner is not always best, as has been 
found in microbial profiles in developing countries. Here the familial environment in developing 
countries is also attached to a certain diet and culture. The environment may also dictate 
which disease is prevalent with the household members and of these diseases there is a 
subset that may be transferred to the infant. This is seen generally as certain diseases are not 
prevalent everywhere [34], [35].  
 
 The health status of an infant affects the development of the microbiota, which in turn 
influences the development of a robust immune system [36], [37]. Table 1 shows the main 
pathologies in neonates. Some of the causative agents are household members as discussed 
above. Treatment of these pathologies also has an effect on the infant’s gut microbiota. Table 
1 shows bacterial groups that are pathogenic and how they can cause disease at such an 
early stage in infancy. Furthermore, the treatment duration can be as long as 28 days. Both 







Table 1: Matamoros et al. (2013) describes “ the main pathologies and antibiotic treatment in 




There are 2 categories with respect to how infants are affected by treatments where treatment 
refers to a response to an ailment. The first is when the treatment is taken by the mother 
before or after birth. After birth usually affects breast fed infants as breast milk becomes a 
transport channel for the causative treatment. Studies have shown that, mainly in antibiotic 
treatments, this results in a lower total number of detected microbes [38]. The second category 
is when the treatment taken by the infant. Lower proportions of bifidobacteria are associated 
with antibiotherapy in infants [39]. This therapy affects the development of the microbiota and 
there was found to be a decreased in phylogenetic diversity in the infants gut [40]. This leads 
to the unfortunate onset of neonatal sepsis which is related to decreased phylogenetic 
diversity [41]. Other than treatment for ailments, there are beneficial therapies such as 
supplement with probiotics and prebiotics for infants. Probiotics are live microbes and when 
taken in correctly calibrated amounts, they give a health benefit to the host [42]–[44]. Popular 
probiotic examples include different strains of Lactobacillus and Bifidobacterium. They are 
known to be involved in many different processes in the human host [45] some of which include 
competitive inhibition with other microorganisms, having an effect on the stability of the 
mucosal barrier and communication and exchange with dendritic cells  that present antigens 
[46]. Whereas, prebiotics are a chosen fermented component, that effect a particular shift in 
the microbial composition and/or processes that occur of the gut, thus giving a health benefit 
to the host [47].  
 
 Vast literature shows the benefits of probiotics with necrotizing enterocolitis in preterm 
neonates as it reduces risk of death [48]–[51]. Studies show very few incidents of secondary 
effects from use, that being said, there is a long way to go in terms of standardising [5] work 
done to investigate probiotic use in infants and pregnant women [52], [53]. Overall, they have 
shown positive effects in infants. Some of these effects are protection against infection [54] 
and diarrhoea [55].  Studies that look at growth- and age- discriminatory bacterial species can 
assist in the probiotic design as they are linked to finding a “health-status”  that is associated 
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with a particular microbiome [56]. Extensively tested probiotic supplements have been found 
to be beneficial in improving specific conditions in infants [57].  Studies have also shown that 
probiotic use during pregnancy is beneficial to women who may have disrupted vaginal 
microbiota as it helps maintain the vagina free of pathogenic microorganisms like Candida 
albicans [58]. This is quite important as maternal bacteria are some of the first colonizers of 
the infant gut. In randomized trials, the supplementation was found to be beneficial and can 
alter the infant’s microbiome during and post pregnancy for vaginally delivered infants [59]–
[62]. 
 
There is a long lasting effect that the initial microbial colonisation has on an individual. The 
resulting metabolic and immune programming stems from this colonisation. To support this 
notion of programming, studies have suggested that the recovery of the microbiome after 
disruption but not the phenotype points towards programming [14], [63], [64].This 
programming then has an extensive influence on that individual’s risk of getting a particular 
infection or disease [65]. A study analysing bacterial fatty acid profiles from faecal samples of 
infants 3 weeks after birth, has shown that these profiles differ significantly between infants 
developing atopy (hereditary predisposition to developing allergic diseases [66]) and those 
that are not [67]. 
 
 Another study correlated Bifidobacterium numbers in infancy at the ages of 6 and 12 months 
to the same infants’ obesity and weight at the age of 7 years. It was found that Bifidobacterium 
was in lower numbers for those suffering from weight issues [68]. The studies show the 
predictive power of studying the microbiome with a large sum of the studies showing the 
predictive power with respect to enteric diseases [69]. The ability to predict “healthy” microbial 
compositions which take into account the different factors that influence the composition of 
the microbiome takes us a step closer to developing strategies that result in personalised 
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solutions. One of the key components of the strategies would be to look at microbial profiles 
of individuals first.   
 
As noted before, there are many studies [17], [40], [70]–[74] that focus just on the internal and 
external maternal factors that contribute to the initial bacterial colonisation of a new born [74]. 
Bacteria that is later detected in the infant, has also been detected in the fetal membranes 
[75], [76], amniotic fluid [76]–[78] and umbilical cord blood [22]. These listed factors are internal 
factors. To support the presence of these using an example of the amniotic fluid, the infant’s 
initial bowel release after birth, shows the presence of ingested amniotic fluid that contains a 
complex composition of microbes. This is important, as previously, it was assumed to be sterile 
[25], [74]. Some of the processes for bacterial colonisation are not yet well understood but 
there is a lot of progress towards better understanding the mechanisms. Figure 1 illustrates 
factors that are important to take into account during and after birth and the bacteria that the 




FIGURE 1: Funkhouser  et al.  (2013)  shows sources of microbial transmission in humans 
from mother to child in the figure above [70].  
The diagram shows the different sources that the mothers have with respect to transmitting 
microbes to the infant, the different microbes that are transmitted and the sources that they 
are transmitted from, such as, the oral cavity [77], [79], the mammary glands which are 
situated at the breast [80]–[82], the mother’s vaginal tract [83]–[85], sebaceous skin that 
surrounds the breast [81], [86] , and the intrauterine environment [22], [25], [74]–[77], [80], 




Previous studies have shown that infants born via vaginal delivery have strains that originate 
from the mother’s vagina and gut [89], [90] while those born via caesarean delivery have 
strains originating from environments that the new born comes into contact with which include 
the delivering hospital staff, the maternal skin and other neonates[91]. This is also noted in 
the figure 1. It is interesting to note that these different patterns in microbial compositions are 
able to persist until the age of 1 [92], [93]. Researchers have hypothesized that this difference 
may be indicative of the increased risk of having asthma [94] , obesity [95] and lower levels of 
circulating Th1-associated chemokines [93] for the children whose mode of birth was via 
caesarean section.  
 
Gut bacterial composition is very dynamic in the first weeks after birth with nutrition playing a 
major role in its development [92]. Bifidobacteria and Lactobacilli are typically dominant in 
breast fed infants while mixed fed infants have a more diverse composition of bacteria and an 
increased abundance of  Bacteroides, Clostridium and Escherichia coli  [92], [96]. An increase 
in bacteriodes is also seen as the diet of an infant moves into solid foods, it is presumed that 
the presence of bacteriodes may point  to their role in nutrient utilization [40]. Previously, the 
role of microbes in a host was said to be pathogenicity but now there is an appreciation of the 
beneficial role that particular microbes play [4]. These are starting points where bacterial 
compositions and diversity are dictated, introduction of solid foods will continue the 
diversification. [40], [97]. While it is still unclear when the exact age where the adult-like 
composition is fully established, it starts showing at a young age of 2-3 years where the 
microbiome increases in richness and diversity [98], [99]. It has recently been shown that some 
phyla, for example, bacteriodes may take up to 5 years to stabilize but initial directive and 




As noted above, the microbiome plays different roles to influence the immune system at 
infancy. For example, an immature gut microbiome has been seen in children with severe 
acute malnutrition. It was considered immature when compared to individuals of the same 
age. This indicated that a delay in the maturation of the gut microbiome had severe 
physiological implications, which is due to an upset in the interactive role of bacteria with the 
host immunity and metabolism [101], [102]. It is pertinent to know the effect that different 
compositions have, their roles in the microbiome, how they affect the other systems they 
interact with as well as the role that is played in those systems, such as the immune or 
digestive system in the human host. A notable and important system that is also dictated at 
infancy is the immune system. In affluent countries, it has been found that, the presence or 
lack of specific bacteria has been found to link to the increase in the prevalence of allergic 
diseases [103]. This is because specific species are important to the initially regulating and 
subsequently developing of the immune system [104]. These specific bacteria are not present 
due to lifestyle adoptions in these affluent countries, such as access to and continuous use of 
medication, in particular antibiotics, adopting a particular diet, modernised and cleaner living 
areas and access to a voluntary C-section.  
 
1.2 Impact of developing gut microbiota on health 
 
Here we take a closer look at the impact the gut microbiota has on the health of an infant and 
the impact of health on the microbiota. There has not been a consensus about what microbial 
composition is indicative of a healthy adult but there has been growing directive on what the 
profile may constitute [105]. Studies have been looking to create models, using data with 
healthy infants, in order to predict what a healthy microbiome would be composed of. This 
builds up from the initial establishment that certain bacterial ratios that point towards a healthy 
system. This has been limited to only predictions within a particular sample space as there 
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are many factors that affect the composition. Interestingly, they have been able to model and 
predict, in a given sample space, what a healthy composition will constitute of at early time 
points of 6 and 18 months in Malawian infants [56], and similar models have been created for 
the Bangladesh samples [102]. Figure 2 takes a look at some factors that are at play in terms 
of defining the diversity and abundance in the microbiota. It is interesting to note how the 
health of an infant is affected by the different shifts in abundances. Moving forward, it may be 
interesting to look into how normal gut development links to particular age-discriminatory taxa 
and how this translates to other samples in different geographic areas. Figure 2 also shows 
how the shifts in abundances differ over time. When comparing the Malawian and Bangladesh 
samples, there were common age-discriminatory taxa but the bacterial species were ranked 
differently in terms of prominence [56].   
 
 
FIGURE 2: Matamoros et al. (2013) shows how the infant gut microbiota is affected by external 
factors and the impact that those factors have on the system. Green upward arrows represent 
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a beneficial change that is made while the red downward ones represent a change that is 
considered to have a detrimental effect on the development of a healthy system in infants  [3].  
 
When looking at the phyla present in a microbial profile, it is common to over look under 
represented populations. Of late, there has been more emphasis on looking at their possible 
vital role in health. Health is achieved through a host of factors; an important one being gut 
microbiota homeostasis. As mentioned previously, dysbiosis usually occurs when controlled 
parameters are disrupted. This has a domino effect as it causes a shift in microbial 
populations, which in turn, is associated with pathological states such as obesity and 
diarrhoea. The causative agents of the initial disturbance may be immune imbalance, 
xenobiotics or changes in dietary intake [3]. An example of such phyla, that may be 
underrepresented, is Actinobacteria (Bifidobacterium), where Bifidobacterium is noted in 
figure 2 to have an impact on the intestinal microbiota of an infant [106] [107]. One interesting 
factor that has been studied widely is the Firmicutes/Bacteroidetes ratio. These studies have 
looked at their variation with respect to diet, in particular, comparing western and rural diets. 
The rural diet is vegetable-based [97]. Metabolic disorders and obesity were found to be 
strongly linked to the ratio [108] [109]. Another important one is the ratio between Prevotella 
and Bacteroides that also correlates well with microbial profiles but of healthy adults [110], 
[111]. Prevotella was found to be enriched in high fibre and plant based diet and had an 
association with carbohydrates and simple sugars with children and adults having healthy 
microbial profiles [112]. In contrast, Bacteriodes was associated with a rich, long term animal 
diet which encompasses saturated fat and several amino acids [97], [111], [113]. 
 
It is interesting to note the various roles the microbiome plays with respect to health. Above 
we have noted external factors that affect the development and overall composition of a 
microbiome. Taking a closer look at the mode of delivery, it has been shown to have an effect 
24	
	
on preterm infants [26], [114]–[120]. Preterm birth is one of the worldwide [121] leading causes 
of infant mortality. A strong correlation has been found between preterm deliveries and 
intrauterine infections, in particular in births that occur at less than 30 weeks [88], [122]. Efforts 
have been made to identify bacteria that are to blame for unexpected preterm birth. 
Interestingly enough, largely the bacteria that are found in intrauterine infections, are the same 
as those that are commonly found in the female vaginal tract [88]. It is important to note that 
women diagnosed with bacterial vaginosis during pregnancy have a higher risk of preterm 
birth [123].  Interestingly, the composition of the vaginal microbiota is known to change as 
pregnancy progresses, it becomes less diverse [85], [124], [125]. These changes are 
suggested to be adaptive responses as the mother’s body prepares a specific inoculum that 
will be beneficial for the fetus at birth [13]. One way in which this is suggested to take place is 
the presence of microbes, in the mother, that allow for maximal harvesting of energy. These 
are then transferred at birth, in particular vaginal birth, and allow for the same energy capacity 
in the infant [125], [126]. Some of these microbes are known to do so by playing a digestive 
role in the infant’s gut [127]. 
 
As noted previously, infants born from a vaginal birth have a different and better adapted 
microbial composition than those born from a C-section [83]. It  is important to note the long 
term health consequences that are associated with a C-section birth [70]. Of particular concern 
are immune-mediated diseases that these infants are significantly more likely to develop such 
as asthma [128], [129] , allergic rhinitis [130], celiac disease [131], [132], inflammatory bowel 
disease [133] and type 1 diabetes [134]–[136]. This is of great concern as C-section births are 






1.3 Infant Immune system 
 
1.3.1 Gut and oral microbiome on immunity 
 
The gut mucosa plays a significant role in immunity as within it, it inhabits a multitude of 
immune cells. It also maintains a homeostatic environment that allows for efficiency in 
processes, such as, nutrient uptake. In innate immunity, it is one of the first of defences as it 
forms a mechanical barrier that works to keep external pathogens out [138]. The following 
sections will discuss the importance of developing strong innate immunity at infancy. By 
creating a barrier from the luminal contents, the epithelial wall is one of the key components 
in the barrier’s structure [139]. The oral mucosa is another interesting microbiome that also 
plays a role in immunity. As noted earlier, the epithelial plays a fundamental role maintaining 
homeostasis, the oral mucosa has three such epithelial tissues which are regionally variable, 
for example the palate vs the buccal mucosa [140], [141]. Keratinized areas like the palate 
form a strong barrier and are much less permeable when compared with counterparts with 
non-keratinized lining [142]. An interesting protective mechanism that these mucosa use is 
clearing of topmost cells in order to prevent pathogens from inhabiting the surface [143].  
 
The gut microbiota is suggested to have a link to the oral mucosa as their microbiomes are 
the most similar of the human host’s microbiomes despite them being highly divergent [144]. 
This is important as the microbiomes at different locations can become predictive of each other 
[144]. This means, for example, an event/set of events in the gut mucosa may be accompanied 
by a particular is event/set of events in the oral mucosa. This association is also true for shifts 
in the microbial communities present in the microbiomes. For example, in individuals with 
rheumatoid arthritis, the abundance of lactobacillus	 salivarius	 was found to be strongly 
correlated with IgG levels (humoral immunity) in both the gut and oral microbiomes. There was 
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also a positive correlation of the microbe between the two microbiomes [145]. This indicates 
that the different microbiomes have information on the state of other microbiomes [145]. The 
oral cavity is connected to the gut via the gastrointestinal tract. This relationship has seen 
there be manifestations of specific symptoms in the oral microbiome that is indicative of an 
issue in the gut, for example, in inflammatory bowel disease such as Crohn disease [146]. 
Growing research suggests that the oral microbiome can be a source of symptomatic 
information for non-oral ailments [147], [148].  Below is a list of genes whose expression is 
indicative of a change in the immune system which can be affected by microbial groups in a 
different locality, such as the gut. 
 
There are 10 genes of interest, due to their significant roles in immunity, which will be 
discussed. These include cytokines which are involved in immune regulation, chemokine 
receptors involved in immune activation and genes involved in cell turnover (shedding of top 
layers on the epithelial wall making way for underlying layers). 
 
IL18 (Interleukin 18): 
 This gene encodes a proinflammatory cytokine [149] which is powerful with respect to 
proliferating mechanisms that induce IFN-γ production. It plays a key role, alongside IL12, in 
enriching NK cell cytotoxicity and the Th1-mediated immune response [150]. The cytokine is 
produced by macrophages with its precursor being expressed in the endothelial cells and the 






 KRT5 (Keratin 5):  
This gene encodes a structural intermediate filament protein that is produced by keratinocytes. 
The protein is expressed in the epidermis (basal layer) and is associated with the process of 
cell turnover [152]. In combination with keratin 14, they form strong keratin intermediate 
filaments which hold up the epidermis [153]. The protein is found in abundance in the epithelial 
cells but this abundance is dependent on factors such as, the health status in the environment 
that the proteins are in [154]. This implies it to be a good marker when looking at the health of 
epithelial cells. 
 
CASP3 (Caspase 3):  
The gene encodes the enzyme caspase which is a member of the cysteine-aspartic acid 
protease family. It exists in an inactive form in all cells and plays a central role in cell apoptosis, 
in particular in the cascade of cleaving procaspases  [155]. Apoptosis usually occurs to 
maintain a certain number of cells  [156]  but this may also occur when cells are stressed or 
damaged due to factors such as disease [155]. In the latter state, Caspase 3 may also be a 
good marker for health status and immune regulation. 
 
CXCR7 (C-X-C chemokine receptor type 7):  
The gene encodes a chemokine receptor. The Chemokine CXCL12 has been shown to bind 
to the receptor [157]. CXCL12 is a ligand and plays various roles in immune activation ranging 
from maintaining immune stability, which includes activating  proinflammatory signalling [158], 





CCL22 (C-C motif chemokine 22):  
The gene encodes a chemokine that is secreted by macrophages and dendritic cells [160] 
which are key players in the immune system. CCR4 is one of the chemokine receptors that it 
interacts, this interaction causes an effect on chosen target cells [160]. The secreted proteins, 
from the interactions, are involved in maintaining the immune system via their role in 
processes such as immunoregulation, and thus the chemokine has been suggested as a good 
marker for immune status [161]. 
 
 IL12A (Interleukin-12 subunit alpha):  
This gene encodes a subunit of IL12 which is a cytokine [162]. This cytokine is known to target 
NK and T cells. In T cells, it is needed in the induction of INF-γ and lastly is needed in the 
differentiation of th1 and th2 cells [163]. In a review, IL12 was proposed to be a “key modulator 
of immune function” [164] implying it is a good marker for immune status. 
 
 KRT10 (Keratin 10):  
The gene encodes a structural protein, like KRT5, and belongs to the cytokeratin family [165]. 
The cytoskeleton structure of the epithelial cells is made up of these and other products, such 
as microtubules [165]. Depending on the differentiation stage of the epidermis, keratin chains 
are formed by different combinations of structural keratin proteins, for example keratin 1 and 
keratin 10 [166]. This is beneficial in case the cells are at different differentiation stages. The 
combination of keratin 5 with another keratin protein and/or the combination of keratin 10 with 
another keratin protein, in order to form structural links, may be able to represent cell turn over 




 IL7R (Interleukin-7 receptor):  
This gene encodes a cytokine receptor and is bound by the cytokine, IL-7 [167]. This cytokine 
plays many significant roles in immunity, which also implies it would be a good indicator of 
immune activity. These roles include the development of B and T cells and maintaining NKT 
cells [168]. Expression of the receptor has been shown to play an important role in the 
homeostasis between memory CD4+ T cells and the mature naïve ones [169], [170]. 
 
CCL5 (Chemokine (C-C motif) ligand 5): 
This gene encodes a chemotactic chemokine which controls how immune cells move [171]. 
The chemokine is also known as RANTES which stands for “regulated on activation, normal 
T cell expressed and secreted” [171]. One of the roles that CCL5 plays is in directing 
leukocytes to inflammatory sites. CCL5 chemokines that are made by immune cells, such as 
CD8+ T cells, are shown to impede HIV entry to target cells [172]. CCL5 has a myriad of 
important roles in the immune system and its production during disease state may indicate 
that it is a good measure for immunity. 
 
CXCR3 (C-X-C motif chemokine receptor 3): 
 This gene encodes a chemokine receptor, which is a common receptor for a many 
chemokines, such as CCL4 [173] and is under selective expression by T lymphocytes 
(activated) [174]. Once CXCR3 is induced during an immune response, it aids in guiding 
immune cells such as cytotoxic lymphocytes, to the inflammation or infection site (adaptive 
immunity) [175]. During diseased state, in particular, autoimmune diseases, CXCR3 ligands 
were found to be highly expressed while expression of the receptor was also found to be high 
in relation to the T cells present [175]. Increased expression during diseased states may 
indicate it is a good marker to measure immunity. 
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1.3.2 Vaccination and the immune system 
	
Vaccination is important at infancy and helps shape the immune system.  Immunisation 
primarily takes place from infancy into early childhood. This is also the same time that the 
microbiome is being shaped and playing a role in influencing the immune system. In addition, 
it is hypothesized that the microbiota has played a role in contributing to the diversity of global 
vaccine efficacy [176], [177].  
 
Studies have found that a compromised microbiome, which may be due to an unsanitary 
environment, dampened immune responses and efficacy of vaccines when looking at 
responses such as antibody response [178]–[182]. This could be due to the fact that the 
microbiome regulates the immune system that the vaccine is targeting to stimulate. Figure 3 
summarises the role the microbiome is suggested to play in influencing vaccine efficacy. 
Vaccination works by stimulating the immune system to respond using dead or weakened 
antigens. This prepares the host’s memory cells for any future possible pathology by an 





FIGURE 3: Valdez et al. (2014) show “a scheme illustrating how the microbiota may influence 
vaccine responses” [177].  
Numerous studies have shown the bidirectional connection between the gut microbiota and 
the immune system. This connection is also known to play a role in modulating the immune 
system’s response to vaccines. Vaccines work by eliciting an immune response which is 
targeted specifically against the antigen that it introduces into the system. The influence of the 
microbiome on the immune system has an effect on vaccine efficacy, which is dependent on 




The immune system is divided into: Innate and Adaptive immunity, where the innate comprises 
of neutrophils, macrophages, dendritic cells, natural killer cells, innate lymphoid cells, 
defensins and epithelial cells and the adaptive uses B and T cells [184]. One of the important 
roles of some of these cells is the secretion of cytokines in the immune system, (see figure 4) 
which can be expressed by most immune cells, but predominantly by helper T cells and 
Antigen presenting cells, such as macrophages and dendritic cells. An example of the use of 
cytokines, is when bodies that are foreign to the immune system are present, they are 
phagocytosized by Macrophages. Thereafter, macrophages use cytokines to stimulate B and 
T cells responses which are dependent on specific antigens. Other cells are also stimulated 
to respond but in a manner that is not specific. The engagement of T cells by the macrophages 
stimulates them to secrete factors that aid in stimulating immune responses towards the 
specific foreign body present in the system. This cascade effect results in the activation and 
proliferation of other immune cells. 
 
 They are produced as a result of a pathological and/or physiological event occurring in the 
host. As seen in figure 4, cytokines are pleiotropic, redundant, and can stimulate a cascade 
effect resulting in the secretion of more cytokines [2]. Cytokine production has been suggested 





FIGURE 4: Zhang et al. (2007) describe the cytokine network in the figure above [2]. 
There is a myriad of immune cells that work together, and communicate via secreted 
cytokines, to maintain a homeostatic immune system. There are different types of cells that 
are involved, such as macrophages, neutrophils and mast cells, and each has a specific role 
to play, some being more significant than others as roles may overlap [2]. 
 
1.3.3 The immune system and its interaction with the microbiome 
	
From the above, we see how complicated the immune system is and the different components 
that influence and shape it. The microbiome plays an influential role in different ways. It plays 
a vital role in the maturation of the host’s immune responses (adaptive and innate). It is also 
hosts unique immunoregulatory mechanisms that are present solely to avert unwanted 
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immune system activation by innocuous antigens. These antigens include those that are 
expressed by the microbiota [186]. 
            The complexity of the microbiome forms a myriad of interactions. This interaction includes but 
is not limited to the host system. These interactions span out to affect development of the gut 
[16], dental health [187], [188], digestive systems [109], [189], resistance to pathogens [190], 
[191] and the development of immune cells [192]–[194]. It is also important to note that the 
microbiome possesses a large number of antigens and there is danger of cross-reactivity 
between the host, commensal bacteria and pathogens, this has a detrimental effect on the 
host’s system [195]. Table 2 shows some of the bacteria involved in immunoregulation and 
the different roles that they play. 
An example of the indirect role the microbiome may play in the immune system is with respect 
to enteric disease. As noted before, enteric infections are most prevalent during the 2-3 year 
age-period. Causes for different infections have historically been attributed to the pathogen 
but studies have shown an interplay between host factors which include; immune response 
which can be acquired or innate, the commensal gut microbes and age-dependent shift which 
includes diet or state of the microbiome [196]. An example of age-dependant shift is 
Campylobacter infections which are high in <2 years and again in young adulthood, which are 








Table 2: Valdez et al (2014) describe “the immunoregulatory effects of microbiota in the gut” 




As an example we take a closer look at host locale for the disease. The epithelium of the 
intestine is a heterogeneous mixture of cells that are set up to respond to the microbiota which 
is in close proximity. The mixture is also in close proximity to the luminal contents where 
luminal refers to the inner open space or cavity of a tubular organ like the intestines [198]. 
These tight junctions noted above maintain a barrier [199] from enteric pathogen or toxin. The 
cause of barrier defects can be attributed to factors that include the disruption of a healthy 
microbiome [200] as the microbiome is shown to contribute to the processes of maintaining 
function of the barrier [201]–[203]. When the barrier is disrupted and penetrated through by a 
pathogen or toxin, this may result in the contents of the luminal leaking through to the lamina 
propria. The lamina propria is where immune cells reside and the leakage can result in 
detrimental physiological and inflammatory responses. These responses lead to diseases 
ranging from disrupted absorptive function to diarrhoea [200], [204]. This notes one of the 
many indirect roles the microbiome plays in affecting the immune system. 
 
The microbiome is also known to have a more direct effect on the immune system. During a 
malnutrition state in childhood, there are also changes in the structure of the intestines which 
includes the diversity and richness of the microbiome. These alterations result in detrimental 
effects, which result in a high negative impact, altered levels of intraepithelial lymphocytes, 
blunted villi and crypt hypertrophy (which is an enlargement of an organ or a tissue due to a 
subsequent increase in the size of its cells [205]). These effects can be seen in cases of early 
childhood malnutrition and enteric disease and have been linked to developmental issues such 
as impaired cognitive development [206], [207]. The profound cascade effect on cognitive 
function affects the individual’s productivity later and the impact in early life increases the risk 
of chronic diseases in the future [208], [209]. The alterations in the intestinal structure lead to 
dysfunctional nutrient absorption which can be seen in figure 5 [196] and impaired immune 
responses. Ultimately these lead to a decline in growth during the early childhood phase [210], 
[211]. It is notable that in addition to the important roles of energy and nutrient extraction [212]–
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[215], the microbiome also modulates the host’s immune system, protecting it against 
pathogens [216], [217]. 
 
 
FIGURE 5: Kolling et al (2012) show that the molecular, immune and architectural changes in 
the gut mucosa are indicative of the health state in the gut mucosa. Examples of these 
changes include, changes in nutrient absorption (molecular), changes in the depth of crypts 
or height of villi (architectural) and  changes in levels of IgA (immunity) [196]. 
 
As mentioned earlier in this section, colonization and stabilization of the gut microbiome is 
intertwined with development of the immune system [218]. It has been proposed that the 
modulation of the mucosal immune response in infants is carried out by microbiome primarily 
in the gut, in terms of the immune systems response to allergens in the environment (one of 
the most common allergens, for example is pollen from grass [219]) [220]. An association has 
also been made between the differences in the Bifidobacterial populations and the allergic 
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status and atopic diseases in children [73], [104], [221], [222]. Interestingly, studies have 
shown that low microbial diversity later on in infancy (5 and 6 months) was not associated with 
atopic diseases when compared in contrast to earlier on (1 week and 1 month) when it was 
[103]. These results suggest early infancy to be a critical point for health with respect to the 
microbiome 
 
Work has been reviewed to take a further look at the intestinal mucosa and the role of the gut 
microbiota [223]–[225]. It was noted that secondary lymphoid tissues in the gut and intestinal 
mucosa development was dependant on the pattern-recognition receptors on intestinal 
epithelial cells’ ability to recognise particular microbial components [186]. It is suggested that 
some of health issues encountered by infants delivered by C-section may be due to the 
inability of the microbes acquired to interact with the above mentioned receptors [70]. This 
goes on to hinder immune development in the infant which leads to increased risk of immune-
mediated disorders that have been mentioned previously. It is also suggested that this is due 
to the transfer of fecal and vaginal microbes that has occurred over thousands of years. This 
may have created specific interactions between the infant’s gut and the particular microbes 
that initially colonise the gut at birth. These interactions then become quite important for gut 
development. Perhaps with time, interactions between microbes acquired via a C-section birth 
and the infant’s gut will begin to form. 
 
Breast milk bacteria are also suggested to play a role in the maturation of an infant’s immune 
system. In particular, in acquired and natural immune responses, where some bacterial strains 
are able to modulate these responses [226]–[229]. The functions, with respect to modulation, 
are variably flexible which hinges on the current state and environment in the gut. In the case 
where there is lack of an inflammatory stimulus for cells developed in the existence of 
lipopolysaccharides, the macrophage production of Th1 cytokines is enhanced in the 
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presence of Lactobacillus fermentum CECT 5716 and Lactobacillus salivarius CECT 5713. 
These Th1 cytokines include IL12, IL2 and TNF-α (inflammatory mediator) [226]. A study has 
confirmed the broad array of effects that these two strains have on the immune system. Some 
of these include the strong induction of a wide array of anti- and pro- inflammatory chemokines 
and cytokines, potent activation of NK cells and activators (moderate) of regulatory, CD8+ and 
CD4+ T cells  [230], [231]. A dominant bacterial group in milk, viridians streptococci, is seen 
as a key component in a healthy infant’s gut when compared to the gut of infants suffering 
from atopy [232]. Generally, the bacterial components of human milk have the potential to be 
involved at a metabolic level in infants which will aid in creating and shaping a healthy 
microbiome in the infant’s gut [233], [234]. Some metabolically active strains from human milk 
like lactobacilli are known to be quite active in the infant gut. They are known to increase the 
chief source of energy that is used by colonocytes and compounds that are pertinent in 
intestinal function maintenance. In the case of colonocytes, they amplify the creation of 
functional metabolites, as an example butyrate (energy source) [235], [236]. It is also 
interesting to note that mammals are reliant on microbes to break down undigestible 
components and butyrate is a product from this process [237]–[241].  Identification of 
metabolites that are derived from commensals by innate immune cells is quite important in, 
for example, responding to not only intestinal injury but a host of ailments ranging from 
allergies to arthritis [242] . Gut bacteria are also noted to be involved in active process of 
inducing dendritic cell (antigen presenting cells) maturation [243], an important stimulus for 
developing lymphoid tissue that is associated with the gut and promoting antiallergenic 
processes [244]. The gut microbiota also plays an indirect role in the immune system. Signals 
derived from it are responsible for the development of most IFNγ-producing (Th1) and IL-17 
(Th17) T cells that are found in the gut [193], [245], [246]. Consequently, changes in the gut 
microbiota result in alterations in the immune system [247]. For example, a decrease in gut 
commensals due to the use of antibiotics results impaired B and T cell responses against 




Figures 6 and 7 show various ways in which the microbiota influences the immune system to 
promote and aid in providing immunity. Failure to regulate the response noted below, via 
disruption of the microbial environment, may result in pathological issues such as allergies or 
inflammatory bowel diseases [249]–[252].  
 
 
FIGURE 6: Belkaid and Hand (2014)  show “the promotion of immune regulation by the 
Microbiota during Steady State and inflammation” in the figure above [186]. 
Left: Homeostasis, commensals are shown to promote immune activation by inducing 
regulatory T cells in a localised manner via the release of metabolites and/or microbial 
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products that are sensed by T or dendritic cells. Furthermore, commensals are shown to 
promote Th17 cells induction. The Th17 cells are involved in the regulation and maintenance 
of a homeostatic environment in the epithelial cells. Right: Inflammation, The microbiota uses 
similar mechanisms in its role in inflammation where metabolites from commensal metabolites 
affect inflammatory cells either in a systematic or localised manner. As an example, short 
chain fatty acids (SCFAs) which are produced by microbes in the gut can inhibit the activation 
of neutrophils. Inflammatory monocytes that enter a tissue can respond to ligands that are 
derived from microbes, in doing so, the monocytes produce mediators. The mediators 





FIGURE 7: Belkaid and Hand (2014)  show “the promotion of protective immunity by the 
microbiota” in the figure above [186].  
The microbiota and its host have a symbiotic relationship whose balance is hinged on many 
factors, some of which include the presence of mutualistic, commensal and parasitic microbes. 
The status of a microbe with respect to being mutualistic, parasitic or a commensal is 
dependent on a host of factors as well, such as, the disease state of the host. Disease has 
been shown to influence microbe’s capacity to shift from a commensal to a parasitic state 
(dependent on co-infection, the state of activation by the host or localisation) and in other 
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instances the commensals are known to act against potentially pathogenic microbes. In the 
instances where they act against the potentially pathogenic microbes, they employ various 
mechanisms, such as, competing for nutrients or releasing metabolites or molecules that are 
antimicrobial in order to have a negative impact on the survival of the pathogen. Another 
mechanism, that is indirect, is when commensals promote the release of antimicrobial 
metabolites by other cells, such as, epithelial cells and reinforcing the tightening of the 
epithelial junctions. Commensals are also known to modulate the function of immune cells 
systematically (cascade effect of immune activation) or locally. In an uncontrolled state, these 
functions of the microbiota can result in autoimmune diseases [186]. 
 
1.4 Diet and the microbiota 
	
As mentioned previously, diet assumes a significant role in the development of the immune 
system. At infancy, there are limited types of feeding possible and can be split into these 
categories breast fed and mixed fed. Mixed fed refers to the infant consuming anything else 
in addition to or replacement of breast milk.  Long term intake of a particular diet results in 
changes in the structure of the microbiome [253]. Studies have been done to look at the short 
term effect and it has been found that there is also a change in structure but the microbiome’s 
composition reverts back after the short term period is over [254].  Predicting the time and 
reproducibility of the change in the microbiota is still unclear. That being said, work that has 
been carried out in inbred mice has shown changes in the microbiome (due to a shift in 
macronutrients in the diet)  manifesting in the space of one day [255], [256]. 
 
 By contrast, work done in human cohorts has shown this time frame change being seen only 
after weeks[257]  and/or even months [109]. In the human cohort studies, there was failure to 
establish significant effects of specific diets [111]. The studies have managed to show the 
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changes in limited bacterial taxa as they respond to the change in diet [258], [259]. In addition 
to the use of probiotics, work has been done to see the effect of diet as an intervention method 
in altering the gut microbiota. The results showed significant difference in β diversity but no 
significant difference in α diversity as shown in figure 8. As noted above, after the diet shift 




FIGURE 8: David et al. 2014 shows “how short-term diet alters the gut microbiota” [253].  
a–e shows ten individuals that were investigated through the course of each diet where PB is 
plant based and AB is the animal based diet in the description that follows: 
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 a) PB diet, fibre intake increased from the median baseline amount whereas the AB diet was 
negligible. b) AB diet, doubling in daily fat intake but a drop in the PB diet. c) AB diet, rise in 
protein intake and a decrease in the PB diet d) No significant change in alpha diversity for 
both diets. e) AN diet, decrease in the similarity between gut microbiota of individuals when 
compared to the baseline communities. The differences in community could be tracked by 
tracing dye and were seen in 1 day after the dye indicated that the AB diet had reached the 
gut. The blue arrows present show the days when the first and last meals of either diet were 
taken [253]. 
 
It is important to note that the genus Prevotella is one of the top sources of inter-individual gut 
microbiota variation [110]. This genus is also hypothesized to show sensitivity from the long 
term intake of fibre [111], [112]. It was observed that there was significant positive correlation, 
over a year, between the subjects’ fibre intake and the baseline levels of gut Prevotella. In this 
study, diet was noted to alter the expression of genes and the activity of the microbes. 
Secondly, food borne microbes that are specific to a diet are detectable in the gut. Lastly, 
particular diets e.g. have different bi-products an animal diet produces bile acids  [253].  These 
bi-products may have a downstream effect and this study shows the presence of a secondary 
bile acid (DCA) that is described to advance the damage of DNA  and hepatic carcinomas  
[260]. 
 
Studies have been done to look at the diet of infants who are either exclusively breast fed or 
are mixed fed. In some cases, formula fed infants are considered in the mixed fed category. It 
has been found that this feeding type impairs the maturation of the infant’s immune system 
[261] which also alters the metabolism later on in the course of life [262]. Generally, formula 
feeding is accompanied by an increase in bacterial diversity [38] but with a decrease in the 
prevalence of beneficial bacteria like Bifidobacteria, and increased prevalence in potentially 
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problematic ones like E. coli, Bacteroides fragilis [263], [264]  and C. difficile [263]. The use of 
certain probiotics with formula milk has been seen to give a similar effect and benefit to the 
development of the gut microbiota as that of breast fed infants [265]. Table 3 lists some 
measures to aid in restoring or developing a mature gut microbiome in infants, this spans not 
only feeding type but other major influencers like mode of delivery and the presence of 
antibiotics [266]–[268]. 
Table 3: Mueller et al. (2015) show the “perturbations to the assembly of the neonatal 






 Exclusively breastfeeding is recommended and has many advantages. Breast milk contains 
a host of beneficial constituents which antimicrobial peptides, immunocompetent cells, 
polyamines, fatty acids,  human milk olisaccharides(HMOs) [269] and lysozyme [186], [270]. 
The bacteria present in milk were once thought to be contaminants, but now are known to be 
inhabitants [271]. For example, with one of the beneficial properties; antimicrobial peptides 
[272] are responsible for inactivating pathogens either additively, individually or synergistically 
[273]. HMO’s, the third largest component in milk [233] are known to have an important 
function in driving microbial diversity in the gut of the infant [274]. HMOs secreted early in the 
lactation cycle have been demonstrated to be used by particular phylotypes of Lactobacilli and 
Bifidobacterial[275]. Interestingly, there has been recent work that revealed two Bifidobacterial 
strains have had many alterations in order to utilize milk within the infant microbiome [276], 
[277]. It is hypothesized that the structure and functioning of the microbiome has been adapted 
to suit the human host [11], [224]. Exposure to bacteria in milk has also been known to improve 
the intestinal barrier functionality as it decreases the permeability of the intestine [278] while 
increasing the production of mucine [272]. It is suggested that an infant’s exposure to the many 
different bacterial phylotypes may assist in aiding against diarrheal and respiratory diseases, 
lessen the probability of getting other diseases like obesity [279] or diabetes [81], [280] and 
reduce the incidence of infection in an infant [281]. Breast feeding provides a secondary route 
for transmission of maternal microbes [282] and stimulates maturation of infants gut [17], [283]. 
This was also noted in primates such as rhesus monkeys [284]. The microbes that are 
transmitted are implicated in playing a role in the immune system development  [226] and 
resistance against possible infection [250], [281]. Another important role that they play is 
protection against possible ailments such as asthma [285], [286] and allergies later on in 
childhood [282]. Literature also shows that breast milk has a selecting effect for particular 
microbes that inhabit the infant gut and seeds for them too [287], [288]. Studies have also 
shown that the milk microbial composition changes over time. It is suggested that this is to 
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prime the infant to move towards a mixed fed diet that needs digestion of solid foods, which is 
assisted by a particular microbial composition. The change over time can be seen from initial 
(immediately after birth) inhabitation of beneficial lactic acid bacteria (Staphylococcus, 
Streptococcus, and Lactococcus) and later, after 6 months, an increase in oral cavity 
inhabitants (Veillonella, Leptotrichia, and Prevotella) maybe, as noted above, to prime the 
infant for the uptake of solid food [82].  Furthermore, the sebaceous skin tissue that is found 
around the nipple and breast milk do not share many taxa [81], [86]. Thus the presence of 
some microbes like Streptococcus, a dominant phylotype in infant saliva [289], may be as a 
result of the suckling action on the breast (flow from the oral cavity and back to the milk ducts 
[290]) [291].   
 
An ‘obesogenic’ environment, which is largely as a result of modern living and diet, leads to 
excessive body fat accumulation which results in various diseases. One of the most prominent 
and problematic one being obesity [292]. Obesity is associated with a decrease in the phylum 
Bacteroidetes but an increase in the phylum Firmicutes, this was observed in some studies 
[109], [293] but not in all of them [294]. The inverse, with respect to increased and decreased 
phyla, has also been reported [295].  Obese individuals were also reported to have an increase 
in Actinobacteria [296].  In the mouse model, for obese mice, the Firmicutes to Bacteroides 
ratio was also observed as obesity related alteration. This ratio was reported as increased in 
the obese mice [297]–[299]. The obese phenotype can be transmitted via transplantation of 
the gut microbiota. This has been done in mice, which indicates that the microbial populations 
in the gut play an active role in obesity pathogenesis [189], [300]. Taking a step further to 
catalogue bacterial genes that are found in the human gut [301] will aid in addressing the 
hypothesis that there is variation of the gut microbiome at a species and gene level. These 
subsets can therefore define different subsets of persons, including adults that are at risk of 





The previous section touched on the interaction between the microbiome and the immune 
system and the current section speaks to the effect of diet on the microbiome. Below is a 
summary figure 9 that shows some of the key interdependent factors that tie in the two 
sections. Work has been done to show how this dependency is affected in disease states such 
as colitis [109], [305]–[308] . In some cases diet affects both the microbiome and immunity 
directly, such is the case with respect to a deficiency in vitamin A [308]. 
 
 
Figure 9: Belkaid and Hand (2014) show the interdependence of diet, immune, and microbiota 
in the figure above [186]. 
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Evidence of bidirectional interaction between the three key factors now exist and is illustrated 
in the diagram, where the factors are, diet, the immune system and gut microbiota. For 
example, the gut microbiota, through commensal microbes, influences the functioning and 
development of the immune system. In turn, the immune system has a profound effect on 
nutrient uptake in the gut. It should be noted that the gut also plays a significant role in affecting 
the nutrient uptake process which is dependent on microbial compositions and their activities 
in the gut. The third factor, diet, also plays a significant role which is dependent on the nutrients 
taken in by the host and is in turn affected by microbial compositions in the gut and the 
functioning of the immune system. [186]. 
 
1.6 Study aims and objectives 
	
There is need for more work to be done to not only look at the microbiome in infancy but the 
different areas that it effects such as the immune system This is pertinent at infancy as this is 
where it is dictated and has some detrimental long term effects on the individual. The aim of 
the project was to investigate the influence of gut microbiota on the immune system in infants. 
This was done using fold change in gene expression levels as indicators to determine whether 
there is an influence on the immune system. The data shows the microbes present in the 
collected stool samples and the gene expression level responses from blood samples of 
infants.  
 
The main objectives of this study were to use infant stool samples to determine: 
1. The influence of diet on the microbiome by comparing samples based on feeding type.  
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2. The subsequent impact of the microbiome on the immune response by looking at the effect 
of feeding type on gene expression levels. Gene expression levels are indicative of the 
production of cytokines that are produced to respond to events in the immune system. 
















As described in chapter 1, the microbiota plays many significant roles; one of which is an 
immunoregulatory one. Studies have migrated from showing what impacts the microbiota to 
what the microbiota, in turn, impacts. It is important to note that the microbiota is dictated at 
infancy and that some of the key processes that it in turn affects are also determined at this 
point. Limited work has been done to look at that pipeline as a whole. Numerous studies have 
looked at what goes into influencing how the microbiota is shaped while others looked at the 
different roles the microbiota plays. It is of particular importance to note how the microbiome 
is dictated and is influenced; this will be of great importance in future to aid in personalising 
efforts to counter, for example, immune related ailments. 
 
In this work we look at the microbiome of infants at 0, 6 and 14 weeks, having been given 
information on the feeding modality. We then also look at the gene expression levels when a 
vaccine (BCG) antigen is introduced to the infant’s system. The time points are quite early but 
studies have shown that the diversity and abundances of an infant’s microbiome already begin 
to take shape at 1 week. 
 
2.2 Sample collection and processing  
 
Information and data from the primary study were kindly supplied by Dr. Heather Jaspan who 
is a Principal Investigator from the Division of Immunology, Health Sciences faculty at the 
University of Cape Town. The primary study is titled: Early Introduction of Non-Breast milk 
Foods Activates HIV Target Cells in South African Infants (HREC REF (Ethics code): 
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571/2010). The sample collection and data generation were carried out by Dr Jaspan’s 




A total of 156 infants were recruited to the study.  One mother that was initially enrolled in the 
study tested positive for HIV, and therefore was excluded from the study. 101 (65% returned 
for follow-up at 6 weeks and 85 (55%) completed the study until 14 weeks. Although most 
mothers that did not return for follow-up visits could not be reached (60%), the most common 
reason provided for not returning for later visits was that the mother and/or infant had relocated 
to outside of the community (21%).  Due to the non-visits (for the study) for various reasons, 
such as relocating, there are some gaps in the data. 
 
2.2.2 Cohort Recruitment 
 
A total of 156 infants were recruited at within 12 hours of vaginal delivery from the maternity 
ward at the Site B Clinic in Khayelitsha, Western Cape, South Africa, into a prospective cohort.  
At the time of enrolment, the mothers of all enrolled infants indicated that they planned to 




 Exclusively breastfed (EBF) infants were considered as those reported having received only 
breast milk and prescribed medicine at that and any previous time point. By 6 weeks of age, 
44 (43.5%) of the infants in the cohort were no longer EBF. This dropped further to 20% of 
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infants by 14 weeks of age. Of the foods that were introduced by 6 weeks, 73% were solids, 
predominantly in the form of porridge or cereals.  
 
2.2.4 Sample Collection 
 
If an infant had stool in their diaper at their study visit, a stool sample was collected, 
with caution to avoid stool that was in direct contact with the diaper.  If stool was not 
present at the study visit, mothers were provided with a sterile sample cup, and 
instructed to collect stool and return the sample cup to the clinic the morning after 
collection. After collection, stool was stored at 4C for no more than 6 hours before transport 
to the laboratory, where the stool was immediately placed at -20C. Stools were thawed, and 
then treated with a cocktail of mutanolysin (25kU/ml, Sigma Aldrich), lysozyme 
(450kU/ml,Sigma Aldrich), and lysostaphin (4kU,Sigma Aldrich).  Stool was then mechanical 
disrupted with a bead-beater (Yuan 2012). DNA was extracted, using the MioBio Powersoil 
DNA kit. The quantity of extracted DNA was then assessed by Qubit dsDNA high sensitivity 
reagent (Invitrogen).  Isolated DNA, suspended in water, was frozen at -80C until sequencing. 
 
Blood samples were also collected. Oral cytobrush samples (OralCDx Brush; OralCDx 
Diagnostics, New York, USA) and saliva samples (Salivette; Sarstedt, Germany) were 
collected at each study visit. The data supplied from the blood sample collection only 
contains information on cytokine response for the infants at the 3 time points. Peripheral 
blood mononuclear cells (PBMCs) were isolated from each sample within 8 hours of sample 
collection, using Ficoll (Sigma) density gradient separation.   PBMCs were slowly cooled to -
80C in Dimethyl sulfoxide (DMSO) (Sigma) + 10% Fetal bovine serum (FBS) (vendor), and 
transferred to liquid nitrogen for storage.  PBMCs were stored in liquid nitrogen for no more 
than two years before analysis. 
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2.2.5 Oral Cytobrush RNA Processing 
 
Samples of the oral epithelium were collected to evaluate if immune activation was evident at 
the site of HIV exposure in breastfed infants (HIV status was examined as part of a separate 
study). Samples were collected with the Oral CDx brush, which was immediately placed into 
RLT lysis buffer (Qiagen, Netherlands) and stored at 4C until transport to the Jaspan 
laboratory. Samples were then placed at -80C and shipped on dry ice to the Sodora laboratory 
in Seattle, Washington, USA for processing.  RNA was isolated from each sample, using an 
RNeasy kit (Qiagen, Netherlands).  RNA was eluted in water, and then quantified on a 
Nanodrop (NanoDrop, Delaware, USA).  All oral sample mRNA processing and analysis was 
performed in the Sodora Lab in Seattle, WA. 
 
2.2.6 Oral Cytobrush qPCR Sample Processing and Analysis 
 
Quantitative PCR (qPCR) was employed to measure expression differences by feeding 
pattern and age. 10 genes were selected for qPCR which are IL18, KRT5, CASP3, CXCR7, 
CCL22, IL12A, KRT10, IL7R, CCL5 and CXCR3. RNA was converted to cDNA with 
SuperScript III (Invitrogen, California, USA).  Taqman Universal Master Mix (Applied 
Biosystems, California, USA) and Single Tube Taqman Assays (Applied Biosystems, 
California, USA) were used to set up qPCR amplification reactions, which were run on a 7500 
Fast Real Time PCR System (Applied Biosystems, California, USA) for 40 cycles.  Thresholds 
were set for each gene in the linear range of the curve.  Fold changes were then calculated, 
using the Comparative Ct method, using RPLP0 or MAPK3 as endogenous control gene and 
the median exclusively breastfed value for each gene as the reference sample. The fold 
change was calculated relative to the mean of the exclusively breast fed samples at each time 
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point  All oral sample mRNA processing and analysis was performed in the Sodora Lab in 
Seattle, WA. 
 
2.3 Method to study Microbiomes (16s rRNA Sequencing) 
 
There are 2 main methods that are used when analysing microbiome genomic data, these are 
shotgun metagenomics and 16s rRNA. Studies have compared these methods against each 
other with respect to their strengths and weaknesses in classifying data [309]. Metagenomics 
takes a step further to look at the functionality of the identified microbes [310] and has been 
added to the Future work section. For purposes of this study, 16s rRNA sequencing was used 
as the scope was to identify the different microbes present and is less expensive compared to 
metagenomics [309].  
 
16S rRNA is a constituent, in addition to ribonucleoproteins, of the 30S small subunit of a 
prokaryotic ribosome and is a housekeeping gene [311].The 16S rRNA gene is targeted as it 
is a ubiquitous gene in bacteria and the gene itself is large enough to use for informatics 
purposes [311]. Sequencing of this gene aids in obtaining information on microbes without 
culturing them [312], this is particularly important for bacterial species that cannot and have 
not yet been cultured. It is also more sensitive to detection than culturing methods [313]  as 
the 16S rRNA gene is highly conserved in bacteria as it is essential in the translation process 
[314]. There is a benefit to the genes being highly conserved, this allows for the construction 
of universal primers [315]. The gene also provides enough phylogenetic information that 
allows identification of a bacteria [316]. One is able to infer phylogenetic relationships because 
the gene is a molecular clock (evolves at relative constant slow rate) [317]. Over time, as the 
gene has become the standard, the phylogenetic information on the gene has accumulated 
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and has been stored in databases that one can check against, which makes it easier to identify 
novel bacteria  [318]. 
 
Within the 16S rRNA gene, there are variable and conserved regions. The variable regions 
have different bases present for different species, which facilitates development of methods 
to amplify the region and distinguish species. The conserved region, as mentioned before, 
allows for universal primers to be designed that target all bacteria. Another important factor 
that has developed over time, as to why the gene is used, is that it well studied and 
characterised (mainly due to ease of sequencing [311] and a simplified amplification technique 
[319]) which has resulted in information being readily available through databases such as 
GreenGenes. 
 
With respect to the variable region, the V4 (variable region 4) hypervariable region was used 
in this study. This species-specific region allows for identification of different bacteria [320], 
[321]. It is also one of the most consistent and dependable sections that are representative of 
the complete region of 16S rRNA sequences that can be used in the phylogenetic analysis of 
most bacterial phyla [322]. There is no apparent consensus (this is also apparent in literature 
[323]–[328]) as to which hypervariable region is most optimal for use, the top contenders are 
the V3 and V4 regions [322], [329], [330]. Efforts have been made to investigate which 
hypervariable regions work best for different organisms and groups of organisms that are 
commonly investigated. The V4 region is of particular interest and is popular due to its short 
length. The length supports quicker less expensive runs that come with simpler working 
protocols but advances in technology and primer design are working towards better 
implementation of longer variable region like V3-V4 [331]. 
 
 The first step in analysing microbial communities begins with extraction of DNA from a primary 
source, which in this case were infant stool samples. Once the samples are extracted, they 
are amplified via PCR at the V4 region of the 16S rRNA gene and a fastq file with sequenced 
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data is produced [332]. The forward primers comprise of MiSeq sequencing adapters (12 
nucleotide Golay barcode, error correcting barcode) which are followed by bases that match 
the 16S rRNA gene [333]. The reverse primer on the other hand is not barcoded [334]. To 
maximise the accuracy of assignment and retention of sequences, it is advised to use Golay 
barcodes as the QIIME (Quantitative Insights Into Microbial Ecology) default settings are set 
to detect these error barcodes [335]. 16S rRNA gene sequences were generated on the 
Illumina MiSeq platform [335]. 
 
2.4 Data processing workflow 
 
The QIIME (version 1.9.1 was used) pipeline takes generated sequence files (fastq files) as 
input as well as a generated mapping file which has data from of the different samples. The 
pipeline was used for quality filtering of DNA sequences, demultiplexing, taxonomic 
assignment (includes generating OTU tables), and calculating α and β diversity [336], [337]. 
A description of the pipeline is illustrated in figure 10 and includes the downstream analysis 
[338]. The V4 region of the 16S rRNA gene was amplified using universal 515F/806R primers, 
and quality checked with Bioanalyzer (Agilent). The samples were sequenced from both ends 
with the Illumina MiSeq platform to generate sequence data. The 16S rRNA diversity analysis 
starts off with quality control and processing in QIIME and afterwards analysis in R using the 
phyloseq package.  




FIGURE 10: Flowchart of data processing up to the analysis stage. 
 
2.4.1 The QIIME pipeline 
 
QIIME is used for raw data preparation and analysis  from high-throughput sequencing of the 
16S rRNA gene [339]. It is an open-source bioinformatics software package that is useful in 
aiding to prepare and visualise diversity in large datasets [340]. Figure 10 shows the flowchart, 
the QIIME pipeline uses from the pre-processing to processing stages. The pipeline can also 
be used for interactive visualizations and statistical analyses [335]. In our case, phyloseq was 
used for analysis as it allows for further expansion on analysis of the microbial samples. 
Phyloseq allows for this expansion as it is a package in R and is thus able to integrate different 
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types of data from a range of sources as it is able to leverage and make use of other useful 
packages in R [335]. QIIME has third party package dependencies. These third party 
packages dependencies are used because they are benchmarks in terms of performing their 
particular task. Although having a large number of dependencies creates complexity in a 
pipeline, the upside is the incorporation of familiar benchmark software which in many cases 
has become the standard go to for use. An example, of a third party package dependency, is 
the UCLUST program that is used for clustering sequences into OTUs [341], [342]. Using 
already established package dependencies also avoids attempting to recreate packages as a 
new created package (which is not as tried and tested) is likely not able to preserve the 
integrity of the functionality needed.  
 
The key tools [335]  that were used in the default QIIME pipeline were: UCLUST which is 
described above as being used to pick OTUs (this is under processing in figure 10); USEARCH 
[341] which is also used for picking OTUs and chimera checking (pre-processing in figure 10); 
RDP Classifier [330]  which is used for assignment of taxonomy; GreenGenes Database [343] 
which is used as a reference database for reference-based picking of OTUs and  assignment 
of taxonomy; PyNAST [344] which is used for multiple alignment of sequences, and lastly 
UniFrac [345] which is used as a phylogenetic metric that can be used for beta diversity 
analysis. 
 
The QIIME pipeline steps shown in the flowchart in figure 10 are described further below: 
Pre-processing (Trimming barcodes and primers, quality control and chimera 
detection): 
As multiple sequences are combined in a single run, they need to be linked back to the 
individual samples. This is done via use of the DNA barcodes in the mapping file which are 
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unique to each sample so as to assign the corresponding sequences back to the samples, 
this is known as demultiplexing. Error correcting codes are also incorporated if they are 
available. The demultiplexing process also involves the removal (trimming) of barcodes and 
primers thus leaving just the matching 16S rRNA gene [335]. 
 
Quality control follows after trimming the barcodes and primer sequences. This helps to 
improve accuracy by improving diversity estimates [346]. This is done via the use of a quality 
score that Illumina creates for each nucleotide which is called the Phred score [347]. This 
score is related to the probability that each of the read nucleotides was read incorrectly [335]. 
Any sequences that do not meet a set desired parameter are removed. The parameter details 
include factors such as the maximum number of ambiguous bases which is typically 
represented as n [346]. Default parameter values are also available in the QIIME pipeline and 
were used, as this is recommended practice  [335]. Chimeras are technical and usually rare 
artefacts [348], [349], of amplified sequences that are incorrectly produced from multiple 
parent sequences. The recommended method to identify chimeras is UCHIME [350] which is 
integrated into the USEARCH package. Quality control also includes the removal of OTUs that 
are represented by single sequences, these are deemed to be erroneous as they are less 
reliable and may result from sequencing errors [340]. Additional information on the number of 
OTUs, samples and reads can be found in the supplementary figure 1 and 2. 
 
Processing (OTU clustering and classification): 
Sequences are clustered together if they are more similar than a set threshold percentage 
[351]. Conventionally 97% [352] is used, and was used here for bacterial species but this 
varies from taxa to taxa [353]. There are 3 approaches (de novo, closed and open reference) 
in QIIME for OTU picking. The open reference approach was used for OTU picking, it tries to 
match sequences against a reference database, if there is no match, the sequence is added 
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to the database as a new reference sequence [335], [354], [355], this is the recommended 
approach in QIIME. After clustering of sequences into OTUs, a representative one was picked 
where the default in QIIME is to pick the most abundant. 
 
After OTU clustering, the last step is classification where taxonomy is assigned and sequences 
are aligned. With assignment to taxonomy, the OTUs are linked to an organism. The 
recommended method, RDP classifier [330] and the GreenGenes dataset  [335], [343].  This 
assists in inferring the different roles of members in the microbial community. Sequence 
alignment is important in order to infer the resulting phylogenetic tree. PyNAST (recommended 
and default) was used for sequence alignment [344]. The method uses a template sequence 
to align the sequences, GreenGenes core set was used and is recommended as a source for 
template sequences [343]. Once sequences are aligned, a phylogenetic tree is constructed 
using the FastTree method [356]. The final step is creation of an OTU table using the 
Genomics Standards Consortium candidate standard Biological Observation Matrix (BIOM) 
format [357]. This was used as input to create a phyloseq object for downstream analysis in 
R. Support for QIIME in R is predominantly achieved by the use of the phyloseq package 
[358]. 
 
2.4.2 Downstream analysis 
 
Data analysis was done in R (version: 3.2.2) using the interface of R Studio 
(version:  0.99.473). The central package used was phyloseq. Phyloseq is an open source 
software package whose purpose is the object-oriented representation and analysis of 
microbiome sample data [358]–[360] and analysis of phylogenetic sequencing data in R [360]. 
This package takes in data from the QIIME pipeline. Other packages used include vegan [361], 
ggplot2 [362], MetagenomeSeq [363] and gridExtra [364]. 
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Chapter 3: Results and Discussion 
As mentioned previously, there were 2 focus areas for this project, oral mucosal gene 
expression levels as indicators of immune activity, and the microbiome in infants with different 
feeding practices. The results of these analyses are expanded on below. 
 
3.1 Oral mucosal gene expression 
 
Firstly, we investigated oral mucosal gene expression over time (see figure 11), separated by 
feeding modality. The samples used were those that had qPCR data for week 6 and week 14, 
where day 0 gene expression levels were always 0 as they were not measured due to the 
babies not yet being fed. Initially, we investigated whether there is a change in expression 
over time, that is, a fold change at the age of 6 weeks compared to fold change at the age of 
14 weeks within the 2 groups, breast and mixed fed. Of particular interest are the mixed fed 
infants that have spikes in their response data (highlighted in table 4). 
 
Secondly, we investigated if there was a difference in mucosal gene expression between the 
breast fed (BF) and mixed fed (MF) infants. As mentioned earlier, diet plays a role in shaping 
the microbiome and the microbiome structure, in turn, has an influence on the immune system. 
An influence of the immune system can be seen in a change in the mucosal immunity. 
 
Figure 11 shows fold change of gene expression levels as they change over time. The initial 
samples show infants who were exclusively breast fed (baby number 32 and 54) then infants 
that moved from breast feeding at week 6 to mixed feeding by week 14 (baby number 52 and 
76). The rest were mixed fed by week 6. There is a clear distinction between the exclusively 
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breast fed infants and their mixed fed counterparts. It is interesting to note that there are 
several spikes in fold change of gene expression level data which were only found in the mixed 
fed data, see red highlighted cells in table 4. As an example, baby number 76 at age 14 weeks 
for KRT5 had fold change of 2207.753. Most of the spikes (high expression fold change above 
6) are found in week 14 with KRT5 having the largest increase. These spikes are present only 
in the mixed fed infants and as discussed earlier, this feeding modality has an effect on the 
development of immunity, where expression patterns of particular genes are indicative of a 
healthy immune system. Over expression of genes such as KRT5 has been associated with  
dysbiosis which may result in disease, for example cancer [365]. Functional studies that look 
not only at gene expression but incorporate metabolic production and protein expression are 
able to paint a clearer picture with respect to deducing whether spikes in expression data are 
point towards an anomaly [366]. The gene expression fold change for CASP3, KRT10 and 
CXCR3 showed no increase. Only samples that had data at both week 6 and 14 were 
illustrated in table 4. The increases may be due to the makeup of their mixed fed diet. As 
mentioned earlier in chapter 1, diet influences the composition of the microbiome and in turn 
the different microbial structures have varied influence on the immune system. This is not the 
case with the breast fed infants as breast milk constitutes a similar makeup.    
 
For the chosen 10 gene expression levels verified by qPCR, there was a difference in 
expression for some genes between the breast and mixed fed infants. This included the 
chemokines CCL5 (Mean log10 fold change at 14 weeks in EBF=-0.419 versus in MF=0.371, 
p=0.004), and CCL22 (mean log10 fold change at 14 weeks in EBF=-0.144 versus 0.251; 
p=0.023). The chemokine receptor CXCR7 was also upregulated in mixed fed infants at 14 
weeks (mean log10 fold change -0.345 in EBF versus 0.020 in MF, p=0.0001).  
 
There were no significant differences gene expression fold change levels of the innate 
cytokines IL12A and IL18 between the exclusively breast fed and mixed fed infants at either 
time point. Both KRT5 and KRT10 were increased in mixed fed infants at 14 weeks (mean 
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log10 fold change in KRT5 -1.790 in exclusively breast fed infants versus -0.139 in MF, 
p<0.0001 and mean log10 fold change in KRT10 -0.361 in exclusively breast fed infants versus 
0.063 in MF, p=0.027). This can also be seen in the highlighted samples in the table. The 
differences in CXCR7 and KRT5 remained significant after adjustment for multiple 




FIGURE 11: Shows fold change of gene expression levels as they changes over time (time points from an age of 6 weeks to 14 weeks) for exclusively breast 
fed (BF), BF to mixed fed (MF) and strictly mixed fed infants. The number under the time points represents the sample (baby) number. The index shows the 
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Table 4: Shows fold change of gene expression for  IL18, KRT5, CASP3, CXCR7, CCL22, IL12A, KRT10, IL7R, CCL5 and CXCR3 over time, levels that had 
spiked values above 10 in figure 11 above are highlighted in red and high values (between 6-10) are highlighted in blue. Breast fed (BF) feeding modality is 
highlighted in green while mixed fed (MF) is in yellow.
Baby number Time since birth Feeding  IL18 KRT5 CASP3 CXCR7 CCL22 IL12A KRT10 IL7R CCL5 CXCR3 
32 6 BF 0 0 0 0 0 0 0 0 0 0 
32 14 BF 0.535243 0.244315 0.631289 0.43296 0.479267 0.365039 0.412436 1.270176 0.955193 1.074565 
54 6 BF 1.793904 0.305302 1.360412 0.554128 0.671199 1 0.541666 1 0.378135 1 
54 14 BF 1 0.667715 0.355501 1 1.658175 1.448896 0.343719 0.613097 1 0.640534 
52 6 BF 0.918552 0.035215 0.898861 1.052647 1 1.527197 1.199659 0.135274 0.05063 0.971952 
52 14 MF 0.348467 1.076195 0.150117 2.431874 0 0.888227 0.283112 0.277202 0.683524 0.479039 
76 6 BF 0 0 0 0 0 0 0 0 0 0 
76 14 MF 0.903009 2207.753 1.139901 4.903127 2.393609 1.264958 6.6683 5.55923 20.0216 1.287211 
24 6 MF 0 0 0 0 0 0 0 0 0 0 
24 14 MF 0.765412 0.760553 1.504608 0.727808 0.163078 2.025093 0.530647 0.081323 2.256358 2.157476 
42 6 MF 7.43502 0.187839 4.011789 0.930873 17.11978 2.963942 3.101734 2.513723 1.429417 1.148336 
42 14 MF 0.945736 8.509831 0.134669 1.814458 0.74395 2.092963 0.954087 0.154922 2.428033 0.449357 
44 6 MF 0 0 0 0 0 0 0 0 0 0 
44 14 MF 0.167671 6.329905 0.22834 4.333907 2.482542 0 1.961526 1.770067 4.234802 0.880492 
47 6 MF 0.084431 0.044554 0.043686 0.550789 0.208046 0.029296 0.097442 0.085671 0.204478 1.559492 
47 14 MF 0.568324 27.37178 0.336254 11.86079 0 1.032985 1.193102 7.992558 21.51336 0.802052 
63 6 MF 0 0 0 0 0 0 0 0 0 0 
63 14 MF 0.45384 36.29756 0.338913 1.550389 1.092119 0 2.800046 0.860292 6.989495 0.778354 
87 6 MF 0 0 0 0 0 0 0 0 0 0 
87 14 MF 0.086298 2.826227 0.071964 0.360869 0.555103 0 1.047017 2.116286 3.536628 0.648651 
89 6 MF 0 0 0 0 0 0 0 0 0 0 
89 14 MF 0.736367 84.28915 0.156161 1.03954 3.947392 8.016209 4.473591 4.654823 19.51849 0.501571 
3.2 Microbial communities (Microbiota) 
3.2.1 Alpha diversity 
As mentioned in chapter 1, feeding plays an important role in shaping the microbiome. 
Diversity measures (figure 12 and 13) are a good way of observing the distribution of microbial 
species and how factors like diet play a role in shaping composition. 
Alpha diversity looks at the richness in species, that is, the mean number of species in a 
habitat or locality [367], in this case, the microbiota of an infant’s gut, by analysing their stool 
samples. The plot_richness function from phyloseq was used in R to determine the alpha 
diversity in our samples. This function “creates plots of richness estimates of each sample in 
a phyloseq data object, allowing for horizontal grouping and colour shading according to 
additional sample variables” [358]. Each point on the graph in figure 12 represents a stool 
sample at a specified coloured time point and is denoted either as mixed or exclusively breast 
fed. The corresponding alpha diversity measure is on the y-axis. Alpha diversity is one of the 
initial enquiries made with respect to phylogenetic sequence data so as to note the richness 
estimates of each sample [360].  Studies have shown that diversity increases over time [20]. 
For example, a particular study that took infant’s fecal samples (in order to investigate their 
gut microbiome) at intervals (from birth until 2 years of age) showed a steady increase from 4 
months [20], [93]. Before 4 months, there were increases and decreases in alpha diversity at 
different time points with no noticeable pattern. Other studies have also shown that alpha 
diversity values can vary [361]. The Shannon index was used because it is widely used in 
studies, like ours, as it best shows richness and rare and abundant species [368]. A decrease 
in alpha diversity, amongst other factors like antibiotic treatment [369], [370] has been 
correlated to disease phenotype [371]–[373]. This may account for alpha diversity not 
separating out over time, from week 0 to week 14 There was a significant difference between 
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the breast and mixed fed infants, Wilcox p-value = 0.01 (p<0.05). It has been shown that alpha 
diversity significantly increases with time, and this is evident in other data from time points that 
succeed 3 months [93]. Our study unfortunately only shows a time point (14 weeks = 3.5 
months) ending just after 3 months with no succeeding time points. The points that showed 
very low measures of alpha diversity may be affected by factors that affect initial colonisation 
such as antibiotic consumption by mothers, which have been known to decrease alpha 
diversity [369], [370], [374].  
 
 
FIGURE 12: Shows alpha (α) diversity (Shannon index) from rarefied data over the 3 time 
points (age of infant). The 3 points are D0=Day 0 in red, W14=Week 14 in green and 
W6=Week 6 in blue. This was compared with BF= Breast fed, MF= Mixed and NA= Missing 
feeding modality data. 
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3.2.2 Beta diversity 
 
Another measure to analyse in microbiomes is beta diversity (figure 13), which goes a step 
further from measuring the number of species (figure 12) within a system to comparing this 
measurement between samples. This basically looks at the number of different microbial 
species between the samples in order to observe if there is a difference between the breast 
and mixed fed infants. This helps to investigate the state of the microbiome, as literature has 
shown that diet affects the number of different microbial species, and this in turn has an effect 
on the immune system. 
 
Beta diversity is a biodiversity measure that is between groups of samples (inter-sample) [85], 
[367], [375]. The plot_ordination function in phyloseq, which is the main function for plotting 
the results of an ordination, was used to create an MDS plot in R to investigate beta diversity. 
Additional factors can be set in the package to effortlessly show a desired sample variable or 
taxonomic rank in different size, shape, or colour to enhance visual aesthetics [358]. Figure 
13 shows diversity between individuals by calculating pairwise ecological distances [358], 
[376], [377][361] to create the MDS [358], [378]. Each point on the graph in figure 13 
represents a stool sample at a specified coloured time point (age). There were no significant 
differences in the breast fed and mixed fed samples. This is evident as no clusters are formed 
by the samples in figure 13, either by the age of the infant or by the type of feeding. Studies 
have shown newborns to exhibit the highest beta diversity, and differences in the types of 
species present, between sampled individuals [20], [117], [119] when compared to later ages. 
The variation has also been shown to start to show a decrease at 4 months which is ~16 
weeks. The samples used ended at 14 weeks, which may be too early for samples to start 
separating out to form clusters, as beta diversity is known to change over time [367]. It is 
shown that over time beta-diversity decreases as it moves towards forming a more stable 
community [20] such changes are also known to be affected by a change in diet [253]. It would 
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be beneficial to study the microbiota in decreased time gaps such as those used in this study, 




FIGURE 13: Shows beta (β) diversity through multidimensional scaling (plotted using Bray-
Curtis distance between samples). The percentages on the 2 axes are similarity values. The 
3 points are D0=Day 0 in blue, W14=Week 14 in red and W6=Week 6 in green. The 
percentage of variation shown by the plotted principal coordinates can be seen on the axes 





3.2.3 Relative bacterial abundance 
 
As mentioned in chapter 1, there are individual species whose presence and/or abundance, 
whether alone or in a group, have an effect on the microbiome and subsequently the immune 
system. These can be viewed in a profile (figure 14). Previous studies have shown microbial 
profiles that point towards a healthy system which in turn is able to elicit an immune response. 
We investigated the relative abundances of the families present in the infant samples to 
determine whether this was affected by diet. The relative abundance was based on all the 
identified genera. It describes the number of microbes of a particular kind as a percentage of 
the total number of organisms of a community, which in this case is the gut  [9], [374]. The 
plot_bar function in phyloseq was used to create a custom function to create the bar plots in 
R. It takes the phyloseq dataset as input and a compilation of random expressions that can 
combine and group the data on the basis of taxonomic rank and different sample variables 
[358]. The microbes described in figure 14 fall within the 4 major phyla that are associated 
with the infant gut microbiota, Actinobacteria, Bacteroidetes Firmicutes and Proteobacteria 
[119], [374]. Other bacteria, also represented figure 14, such as Bifidobacterium, 
Lactobacillus, Lactococcus, and Streptococcus are known to have high relative abundance in 
the infant gut. Their genomes are known to be well represented in some biosynthetic pathways 
such as that for cobalamin [97]. This prevalence can also be clearly seen in the phylogenetic 
tree in figure 15. The relative abundance of lactic acid bacteria that is present in milk, for 
example, Lactobacillaceae (represented in the figure 14) has been found to be important in 
innate immunity [284]. Although diet is known to affect the variance of relative abundances, it 
may be that diet may not have an immediate effect on changing the relative abundance in an 
infant. Although there is no significant difference between the mixed fed and breast fed relative 
abundances, studies show that continued breast feeding at 9 months is associated positively 
with high relative abundances of dominant species such as Bifidobacterium and Lactobacillus 





FIGURE 14: Plot showing the relative abundance of organisms at the family level across the 








3.2.4 Relatedness of bacteria in the microbiome 
 
Another important aspect in microbial studies is the phylogenetic relatedness of organisms in 
a sample. This builds on from figure 14 which looks at the relative abundances and takes a 
step further to look at how these organisms are related (see figure 15). 
 
The phylogenetic tree was produced in order to establish whether the microbiome 
communities that were derived from the stool samples were significantly different [85]. The 
plot_tree function in phyloseq was used to create figure 15 in R. It allows for easy and simple 
graphical representation and/or investigation of a phylogenetic tree, with sample data overlaid. 
Some instances have shown the rendered tree to be a powerful representation of the possible 
underlying evolutionary structure represented by the sample data [358].The phylogenetic tree 
provides an estimate of the degree of divergence between the different representative 
sequences found in the samples [345], [379], [380]. It is also used to capture the evolutionary 
relationship between OTUs [6]. Sequences (OTUs) that are highly similar with each other are 
situated close to each other and linked by connections in branch points which shows that the 
OTUs are phylogenetically associated [120]. It is also interesting to note that even 
phylogenetically disparate microbes have been found to perform similar functions, this is due 
to the fact that the gut has a great diversity of well adapted bacteria [12]. Even though it may 
be important to note the phylogenetically related bacteria, the disparate ones also play a 
significant role. For example, a diverse range of bacteria from sulfate-reducing bacteria to 
methanogenic Archaea have been known to consume H² produced by other fermenting 
microbes [381].  
 
From the phylogenetic tree in figure 15, Firmicutes which contain, the second largest group of 
sulfate-reducing bacteria [382] are distantly related to Proteobacteria (predominantly of the 
genus Desulfovibrio, which are also involved in sulfate reduction [383]) but carry out the same 
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role. This kind of data can assist with looking at compositional patterns of infants that may be 
suffering from a particular ailment and this helps visualise the natural clusters that are formed 
in the gut microbiota [6], [384]. As seen in figure 15, Proteobacteria cluster together. It is 
expected that bacteria that cluster together usually have overlapping roles, functions and pools 
from which they obtain nutrients, so these would naturally compete for resources. This is not 
the case, as seen the different Proteobacteria lineages are just as abundant as each other 
which suggests they are not competing for resources. Studies have shown that similar species 
are more likely to co-appear in samples [385] and in some samples they appear with 








FIGURE 15: Phylogenetic tree at Phyla level which showing the relative abundances. The 
labelled species are those found to be most abundant.  
 
3.2.5 Specific organism abundance 
 
Violin biplots, like heatmaps, aid in getting quick insight into the nature of data and directive 
for future exploration [387]. One of their main advantages is their shape which shows how the 
abundance is distributed [388] for a particular organism. A violin plot takes its initial form from 
a box plot but is able to show dense areas in abundance data through curves and bumps 
[388]. The plots were used to investigate possible areas of future exploration by looking at 
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abundant organisms (figure 16) and picking a popular group in literature such as 
Bifidobacteriales. From here we take a further look at the genera present and their role. 
 
It is important to look at microbes that may be underrepresented as they may have key roles 
in the microbiome. We used violin biplots to visualise summary data as in box plots, this aids 
in gaining insight into the distribution of abundances which is beneficial for directive with 
respect to future exploration. To create the plots, a custom function was created in R which 
utilised the phyloseq function psmelt [359]. Figure 17 shows the relative abundances of the 
most prevalent taxa. The following figures (figures 17, 18 and 19) show biplots of the 
Bifidobacteriales taxonomic order over time. It is interesting to note the changes in relative 
abundances for both Bifidobacterium and Gardnerella. At day 0 Gardnerella abundances 
show high variability, with most samples having the median value of ~0.001 (log₁₀ scale) with 
a range from ~0.00025 (lower whisker) to ~0.085 (upper whisker). By week 14, there is 
decreased variability amongst samples with most samples having the value of ~0.00015 with 
a range from ~0.0001 (lower whisker) to ~0.00025 (upper whisker). This can also be seen in 
Bifidobacterium except, it shows greater variability (from ~0.00015 (lower whisker) to ~0.145 
(upper whisker) at Day 0) and higher abundances. This is consistent with literature that shows 
the gut microbiota abundance variability stabilising over time,  Studies have shown that some 
overlooked underrepresented microbes have the ability to cause pathogenicity [112], [389]. In 
our case, Bacterial vaginosis which has detrimental effects in infants born via the vaginal 
method are associated with anaerobic bacteria such as Gardnerella [124], [184], [390]. Efforts 
need to be put into understanding the effect of underrepresentation of organisms such as 
Bifidobacterium [3] when compared to pathogenic counterparts. Generally, it would be useful 
to move to understand the different impact each microbe has on the infant gut, especially 






FIGURE 16: Violin biplots showing the relative abundance of the most prevalent phyla at day 





FIGURE 17: Violin biplot of the relative abundances of Bifidobacteriales taxonomic Order, 
grouped by feeding modality and genera at day 0. Where BF= Breast fed and NA= Missing 





FIGURE 18: Violin biplot of the relative abundances of Bifidobacteriales taxonomic Order, 
grouped by feeding modality and genera at week 6. Where BF= Breast fed, MF= Mixed and 





FIGURE 19: Violin biplot of the relative abundances of Bifidobacteriales taxonomic Order, 
grouped by feeding modality and genera at week 14. Where BF= Breast fed, MF= Mixed and 
NA= Missing feeding modality data 
 
3.3 Microbial communities and mucosal immune gene expression 
 
Building on from beta diversity, heatmaps are a good way to visualise clustering. They are 
beneficial as they also display the different organisms present in the samples and shows their 
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relative abundance against factors like feeding modality and particular expression levels for a 
gene. 
 
The function used reorders the heatmap based on radial coordinate angle in the first two axes 
of an ordination rather than clustering or being placed arbitrarily [358]. Traditionally, 
hierarchical clustering has been used as a means of organisation but this has been found to 
have the potential to be misleading and lead to misrepresentation of the data in question [391]. 
A customised function, which utilised the NMF (nonnegative matrix factorization) package 
[392] and a phyloseq object for taxa annotation for plotting the OTUs was used to create the 
heatmaps in R. The abundances present are consistent with the current understanding of the 
microbial composition infant’s gut [49], [57], [97], [223]. The lack of clustering of the samples 
in the heatmaps is also consistent with other studies [372], [373], [393], [394] as well as with 
the MDS in figure 13 where the samples are measured at stages (ages) that are too early to 
cluster in terms of feeding modality with respect to abundances of different microbes. 
 
Following from looking at fold change of mucosal immune gene expression levels over time in 
figure 11, the heatmap in figure 21 looks to investigate whether organisms present cluster 
according to the expression changes of genes. KRT5 and CASP3 were picked from the 10 
chosen genes expression as KRT5 had the most noticeable increases in data while CASP3 
had constant values. As discussed in chapter 1, the microbiome influences the immune 
system and the expressed genes are an indication of the state of the immune system. The 
heatmaps aid in stacking fold change in gene expression levels against the relative 
abundances of microbes that were present in the samples. At week 14, Bifidobacterium of 
abundance below 0 (heatmap log₁₀ scale) generally correlates with high CASP3 gene 
expression levels in breast fed babies while abundances above 1 correlated with low gene 
expression levels. KRT5 follows a similar trend as their gene expression levels overlay each 
other in figure 21.These changes are not significant but are in line with the results in beta 
diversity where there is also no significance in the diversity between samples. The 14 week 
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age may be too early for noting the dynamic changes occurring in the microbiome. This 
dynamic nature of the abundances of different microbes may be the reason why a significant 
correlation with fold change in gene expression is not seen.  
 
 
FIGURE 20: Heatmap with dendrograms of rarefied OTUs taxonomic classes (rows) filtered 
at 25% presence (transformed (log) abundances values) to show the effect of feeding (first 
row). Time since birth is shown as D0 = day 0, W6 = week 6 and W14 = week 14 (first row). 
BF, breast fed samples, are represented in purple while MF, mixed fed were represented in 




FIGURE 21: Heat map with dendrograms of rarefied OTUs taxonomic classes (rows) filtered 
at 25% presence (transformed (log) abundances values). Time since birth is shown as D0 = 
day 0, W6 = week 6 and W14 = week 14 (first row).  The diagram shows the effect of feeding 
modality (second row) for two fold change of mucosal immune gene expression levels, KRT5 
and CASP3 (third and fourth rows). BF, breast fed samples, were represented in purple while 
MF, mixed fed were represented in green. The green represents the fold change of mucosal 
immune gene expression levels.  
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Chapter 4: Conclusion and future work 
 
4.1 General Conclusions 
	
From the results section, we have seen a significant difference in the fold change in gene 
expression levels, in all the genes except IL12A and IL18, between infants that are exclusively 
breast and those that are mixed fed. Earlier in chapter 1, there was a note and big emphasis 
on the influence of diet on the microbiome. Studies have shown that different diets result in 
varied diversity and composition of an individual’s microbiome. The altered microbiome then 
has an effect of different systems. In this study, we looked first at the immune system. 
Cytokines, chemokine receptors and structural proteins play key roles in the immune system; 
a shift in their expression levels can be an indication that there has been some influence that 
has caused a change in response. The objectives were to see the influence of diet on the 
microbiome by comparing samples based on feeding type (observed in significant alpha 
diversity measures between the feeding modalities), the subsequent impact of the microbiome 
on the immune response by looking at the effect of feeding type on gene expression levels 
(observed in significant fold change in gene expression between the feeding modalities) and 
the effect of the presence of different microbes on gene expression levels (observed as trends 
in the data). The lack of significance (in correlating individual microbes to fold change in gene 
expression) may be due to the early time point age of 14 weeks where bacterial abundances 
are still dynamic and do not correlate well. This is also supported by the lack of significance in 
beta diversity. More genes and later times points are essential for future work. Significant 
difference, Wilcoxon p-value<0.05 at 0.01, in alpha diversity (figure 12) may account for the 
significant differences in gene expression levels (described in chapter 3) between breast and 
mixed fed infants. This supports the notion that diet influences the development of the 
microbiome (significant differences in the alpha diversity of microbes based on feeding 
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modality) which in turn influences the immune system (significant difference in fold change in 
gene expression levels between breast and mixed fed infants). Alpha diversity looks at the 
mean species diversity but there was no significance difference in the beta diversity between 
feeding types although the different populations may have started to cluster. This may be due 
to the fact that it is quite early in the infant’s life and this is the period when the gut is very 
dynamic the (figure 13).  
The phylogenetic tree in figure 15 is in line with initial bacteria composition that has previously 
been found to be prevalent during the initial colonisation in infants. The heatmaps then go 
further to initially look at the relationship between feeding modality and the microbiome over 
time (figure 20) and examples (figure 21), of the relationship between gene expression levels 
and the microbiome. Other studies have looked at underrepresented bacteria like that in figure 
16, which shows the distribution of abundance for one of the most prevalent phyla. The biplots 
that follow take a look at the taxa Bifidobacteriales. Biplots separate out the phyla to take a 
closer look at the different taxa at play. It is interesting to note the dynamic nature of both taxa, 
especially Gardnerella. Looking into the future, with respect to personalised medicine, it may 
be beneficial to understand their role this may be a more precise and focused target than 
looking at a broad phyla. 
 
Significant alpha diversity measures between breast and mixed fed infants show that feeding 
modality plays a role in shaping the microbiome, which, in turn, influences its 
immunoregulatory role in the immune system which can be seen through the gene expression 







4.2 Future Work 
 
The human body is like a machine made of many components, some more vital than others 
but each playing a specialized role. Some of these vital components like the gut microbiome 
do not work in isolation. It is also important to note that one cannot attribute the development 
of the microbiota to one factor and this creates a need to study how these components work 
in a system to develop a particular microbial profile. Understanding how each particular profile 
can be developed will contribute immensely to the development of personalised therapy and 
medicines[3], [5]. When one understands how a “healthy” microbiota status can be reached, 
as mentioned in chapter 1, this differs by factors such as locality; one can develop therapies 
and medicines that aid in ailments related to a microbiota in dysbiosis. 
 
As important as it is to focus on the gut microbiome with respect to its influence on the immune 
system, it may be beneficial to later on then branch out to look at some of the key factors that 
play a role in influencing the microbiome. In particular how different components relate to each 
other and subsequently how they influence the immune system at infancy. The microbiome 
and the immune system play significant roles at infancy, future work would be beneficial to 
build on the following: 
 
4.2.1 Proteomics analysis 
 
One of the major advantages of proteomics, which is the study of proteomes and their 
functions,  is that it gives a high resolution representation of microbial populations so as to 
look at their function and structure [395]. In addition to other systems-level data, proteomics 
provides beneficial information on identifiable proteins such as enzymes, and thus enzyme 
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activity. Enzymes can also be used to construct metabolic pathways which can reveal 
metabolic functions and carbohydrate transport. It has been shown that activity associated 
with enzymes may have a role in the symbiotic relationship between the microbial community 
of termite’s (Nasutitermes) hindgut and the termite host. [396]. The microbial community is 
thought to provide the means to program the metabolic system and provide knowledge to the 
naive immune system [16], [397]. Although metagenomics is an important step in 
understanding microbiomes as it provides candidate species that are at play, it does not 
provide evidence of their actual involvement in any role or at what level they are involved in. 
This is where functional approaches come in; their aim is to identify active molecules and 
species present in order to decipher the ecological interactions present in the gut microbiome. 
Furthermore, this gives beneficial insight when looking at disease mechanisms (usually 
infection is initiated and propagated by protein molecules) associated with the microbiome and 
finding strategies to evade infection and maintain a healthy microbiome [398]. 
In time it would be beneficial to incorporate the rest of the “-omics”. These include genomics 
(listed below as host genetics), metabolomics, metagenomics and transcriptomics. These will 
definitely open a new and more informed perspective to understanding the infant gut and 
immune system [40]. 
4.2.2 Viral, Fungal and Bacterial microbiome Interactions 
Recent findings from microbiome studies shows interactions between bacteria and viruses 
and how these interactions can influence disease and health in a host [399], [400].  These 
interactions can also affect bacterial compositions in the microbiome. Fungi have been found 
to interact with the gut and are involved in regulating immunity. An example is the prevention 
of inflammation when there is an acute mucosal injury, when commensal fungi interacts with 
C-type lectin receptor Dectin 1 [401]. In the intestines, antiviral immunity is dependent on
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bacterial signalling that is carried out by Gram-negative bacteria [402]. On the other hand, 
enteric viral infections have been found to protect the host against intestinal damage and 
furthermore, pathogenic bacteria [403]. Enteric viruses can have their replication enhanced by 
the gut bacteria. Some of these viruses include rotavirus and poliovirus [403]–[408] where 
chronic rotavirus infection is associated with immunodeficiency [409]. It would also be of great 
importance to have a deeper understanding of bacterial interactions and their contributions in 
the gut [410], [411]. 
 
4.2.3 Biographical information. 
 
It has been shown that first born children have less bacterial diversity when compared to their 
successive siblings. This is attributed to the bacterial transfer between siblings and the 
household hygienic practices  [374]. Furthermore, use of antibiotics by the mother while she 
is pregnant has an effect of the infant’s gut microbiome and future health [412]–[414]. Antibiotic 
use during breast feeding has the same undesirable effects in infants [21]. This is not the same 
case in adults where the microbiome may initially be disrupted due to antibiotic use [12] and 
later, due to resilience, recover to its normal state. Unfortunately infants at this point have not 
developed such a resilience and may fail to fully recover [415]. The microbiome is a complex 
system and disruptions cause shifts in microbial compositions. In infants, the disruption in 
ecology may cause a shift that facilitates colonization of the gut by enteric pathogens [393]. 
Enteric infections are most prevalent during the period of 2-3 years  [196]. An increase in 
biographical information will paint a better picture of what affects colonisation of the infant gut 





4.2.4 Host Genetics 
Following on from biographical information, in particular familial environment, family members 
have been found to have similar microbiomes compared to those of unrelated individuals [97], 
[296], [416], [417]. Of course this can be attributed to the fact that they share a familiar 
environment and have similar dietary preferences, which are strong influencers that shape the 
microbiome [111], [253], [418]. Even so, a large degree of genetic identity is shared between 
related individuals. Discrepancies in the effect of familial environment on the microbiome can 
be attributed to factors such as exposure time, for example, in the case were pets are involved 
[34], [419], [420] where there may be a pet in the house but it is kept outside or away from the 
infant reducing exposure time. This then raises the possibility that familial microbial similarities 
are underlined by shared genetic similarity. Studies have shown how these are related [381], 
[421], others take a generalised approach and look at the link between abundances of gut 
microbiota  and genetic loci [422], [423] while yet other studies have looked at gene-microbiota 
interactions [424]–[428]. It would be important to note the role that host genetics play with 
respect to the development and maturation of the microbiome as studies have shown that 
abundances for particular groups of the microbiome are also influenced, in part, by the host’s 
genetics [186], [421], [429].  
4.2.5 Additional Samples 
One can look to incorporate additional samples from other locations as their microbial 
compositions may play a significant role in initial colonisation and shape the infant’s gut 
microbiome. Studies have been looking extensively at the following microbial communities: 
maternal faeces, meconium (earliest stool sample which contains materials ingested during 
the infant’s time in the uterus) [26], [74], [83], placenta, amniotic fluid [23], colostrum [430]–
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[436], milk samples [282] and vaginal samples (some of these are also dependent on mode 
of delivery.) [78], [394]. Recent studies have suggested that live bacteria in breast milk may 
have originated from the maternal gut. The endogenous route suggested has been recently 
confirmed by independent research groups [282], [437], [438]. This is then important in 
identifying and understanding the different groups that are at play in influencing the infant 
microbiota and its immune system. 
The incorporation of different factors may be a big step but initial smaller steps are already at 
underway with research going into understanding how these different components affect the 
microbiome. The next step then is to see, how collectively these factors influence the 
microbiome and subsequently the immune system. It would also be interesting to include 
research of where the factors mentioned above also play a direct role in influencing the 
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